...
首页> 外文期刊>Metabolism: Clinical and Experimental >Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
【24h】

Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.

机译:术前生长激素对促甲状腺激素释放激素的反应和肢端肥大症的口服葡萄糖耐量试验:50例患者的回顾性评估。

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of this study was to investigate the relationship between growth hormone (GH) dynamic tests (thyrotropin-releasing hormone [TRH] test and oral glucose tolerance test [OGTT]), insulin-like growth factor-I (IGF-I) plasma values, tumor size, and clinical outcome in patients with GH-secreting pituitary adenomas. Furthermore, we investigated the potential prognostic utility of the above biochemical parameters in the follow-up of patients with acromegaly. We studied 50 acromegalic patients (18 males and 32 females; mean age, 40 years; range, 16 to 69) who underwent trans-sphenoidal removal of a GH-secreting pituitary adenoma from 1990 to 1994. Preoperatively, we evaluated (1) GH plasmatic levels after an oral glucose load (OGTT) (blood samples were drawn at -15, 0, 30, 60, 90, 120, 150, and 180 minutes after oral administration of 0.75 g/kg body weight [BW] of glucose), (2) GH plasma levels after a TRH test (200 microg as an intravenous [IV] bolus), and (3) basal IGF-I plasma levels after an overnight fast. From 3 to 12 months after surgery we evaluated (1) GH plasma values after an OGTT, and (2) basal plasma IGF-I, free triiodothyronine (FT(3)), free thyroxine (FT(4)), thyroid-stimulating hormone (TSH), and urinary free cortisol. The same tests were performed every year for 5 years. All of the patients were classified into 4 subgroups according to the system of Hardy and Vezina. Preoperatively, controlled 28) and an unresponsiveness to OGTT (n = 29); 23 of them belonged to the I and II classes. Only 5 poorly controlled patients (n = 21) showed a preoperative paradoxical response to TRH and 9 had a preoperative GH partial inhibition after OGTT; 19 of them belonged to the III and IV classes. Our data suggest that in the preoperative period in acromegalic patients the simultaneous presence of a GH paradoxical response to TRH and lack of GH inhibition after OGTT is inversely related to the tumor size and therefore more likely to be restored to normal by surgical treatment.
机译:这项研究的目的是研究生长激素(GH)动态测试(促甲状腺激素释放激素[TRH]测试和口服葡萄糖耐量测试[OGTT]),胰岛素样生长因子-I(IGF-I)血浆之间的关系分泌GH的垂体腺瘤患者的临床价值,肿瘤大小和临床结局。此外,我们调查了上述生化参数在肢端肥大症患者随访中的潜在预后效用。我们研究了1990年至1994年经蝶骨切除GH分泌垂体腺瘤的50例肢端肥大症患者(男性18例,女性32例;平均年龄40岁;范围16至69)。术前评估(1)GH口服葡萄糖负荷(OGTT)后的血浆水平(口服0.75 g / kg体重[BW]的葡萄糖后,分别在-15、0、30、60、90、120、150和180分钟抽取血样) ,(2)TRH测试后的GH血浆水平(200微克静脉内[IV]快速推注)和(3)过夜禁食后的基础IGF-1血浆水平。手术后3至12个月,我们评估了(1)OGTT后的GH血浆值,和(2)基础血浆IGF-I,游离三碘甲状腺素(FT(3)),游离甲状腺素(FT(4)),促甲状腺激素(TSH)和尿液中的游离皮质醇。每年进行相同的测试,持续5年。根据Hardy和Vezina的系统,将所有患者分为4个亚组。术前控制28),对OGTT无反应(n = 29);其中有23个属于I和II类。 OGTT术后仅5例控制不良的患者(n = 21)对TRH表现出术前悖论反应,而9例术前GH部分抑制。其中有19个属于III和IV类。我们的数据表明,在肢端肥大症患者的术前期,同时存在对TRH的GH反常反应和OGTT后缺乏GH抑制与肿瘤的大小呈负相关,因此更可能通过手术治疗恢复正常。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号